Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Accounts Payables (2020 - 2025)

Celularity (CELU) has disclosed Accounts Payables for 6 consecutive years, with $24.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables rose 59.66% to $24.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $24.6 million, a 59.66% increase, with the full-year FY2024 number at $23.3 million, up 64.71% from a year prior.
  • Accounts Payables was $24.6 million for Q3 2025 at Celularity, up from $24.4 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $24.6 million in Q3 2025 to a low of $5.0 million in Q1 2021.
  • A 5-year average of $13.1 million and a median of $12.4 million in 2023 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: soared 12694.08% in 2021, then crashed 37.64% in 2022.
  • Celularity's Accounts Payables stood at $9.3 million in 2021, then plummeted by 37.64% to $5.8 million in 2022, then soared by 143.44% to $14.1 million in 2023, then surged by 64.71% to $23.3 million in 2024, then rose by 5.54% to $24.6 million in 2025.
  • Per Business Quant, the three most recent readings for CELU's Accounts Payables are $24.6 million (Q3 2025), $24.4 million (Q2 2025), and $23.3 million (Q1 2025).